Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay.

2010 
10516 Background: Although the use of (neo-)adjuvant chemotherapy in breast cancer patients has resulted in improved disease-free and overall survival, not all patients benefit equally. Nevertheless, chemotherapy is still applied empirically, since clinical tests for response prediction are not routinely available. We have evaluated the utility of an in vitro chemosensitivity assay (ATP-TCA) and gene expression profiles in predicting response to neoadjuvant chemotherapy. Methods: Pre-therapeutic core biopsies were obtained from 30 breast cancer patients assigned to three cycles of neoadjuvant epirubicin 75 mg/m2 and docetaxel 75 mg/m2 (Epi/Doc) in a prospectively randomized clinical trial (ABCSG 14). Individual tumor samples were subjected to a standardized ATP-based Epi/Doc tumor chemosensitivity assay (ATP-TCA), and to Affymetrix U133 A+B gene expression arrays. Patients then received 3 cycles of chemotherapy, and tumor response was subsequently evaluated by pre-operative ultrasound and Ki67 expression....
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    33
    References
    1
    Citations
    NaN
    KQI
    []